Mr Perkins is an experienced public company director and has extensive Australian and international experience as a leading corporate advisor on strategy, mergers and acquisitions and capital markets matters. Mr Perkins is Chairman of Woolworths Group Limited and Origin Energy Limited. He is founding Chairman of Sweet Louise, a charity dedicated to supporting women with metastatic breast cancer. He held senior executive leadership positions at Deutsche Bank from 1999 to 2013, including Managing Director and Head of Corporate Finance for Australia and New Zealand, membership of the Asia Pacific Corporate and Investment Bank Management Committee and Chief Executive Officer of Deutsche Bank New Zealand.

Scott_Perkins_Garvan_Chair_Board.jpg

Chair

Scott Perkins

Nominated by the Trustees of St Vincent’s Hospital

The Hon Dr Bennett is a former Judge of the Federal Court of Australia. She is presently Chancellor of Bond University, Arbitrator with the Court of Arbitration for Sport, Chair of the Australian Nuclear Science and Technology Organisation (ANSTO), Chair of Gardior Pty Ltd, the Trustee of The Infrastructure Fund (TIF). Dr Bennett has extensive knowledge and experience in intellectual property arising from her position as a Judge, as a senior counsel specialising in Intellectual Property, as President of the Copyright Tribunal and as former Chair of the Advisory Group of Judges to the World Intellectual Property Organisation (WIPO).

Annabelle_bennett-Garvan_Institute.jpg

Annabelle Bennett AC SC

Professor Crossley is a molecular biologist working on CRISPR-gene editing and blood diseases, and is Deputy Vice-Chancellor Academic Quality at the University of New South Wales. He is an enthusiastic science communicator, Chair of The Conversation’s Editorial Board and Deputy Director of the Australian Science Media Centre. He was a Rhodes Scholar, a recipient of the NSW Premier’s Award for Medical Biological Science, and in 2021 a species of iridescent squid was named in his honour – 

 – Merlin’s butterfly bobtail squid.

Merlin-Crossley-AM_Garvan-Institute.jpeg

Merlin Crossley AM

Nominated by the Garvan Research Foundation

Mr Johns is the independent Chairman of the ASX listed Goodman Group and a director of the European Australia Business Council. He is a former chairman and non-executive director of three ASX listed entities - Brambles Limited, Leighton Holdings Limited and Spark Infrastructure Group - and a former Finance Director and, upon his retirement from executive duties, a non-executive director of the Westfield Group. He has a Bachelor of Economics degree from the University of Sydney and is a Fellow of the Institute of Chartered Accountants in Australia and the Australian Institute of Company Directors.

Stephen_Johns.JPG

Stephen Johns 

Nominated by the Trustees of St Vincent's Hospital

Dr Kelly is a Founding Partner of OneVentures and serves on the investment committee of OneVentures' three main Funds, chairing the Healthcare Fund III Investment Committee, and leads the healthcare and biotechnology practice across the firm. He is currently Chair on the boards of OneVentures investee companies Vaxxas and Hatchtech and is non-executive director of BiVACOR, Clinical Genomics and Prota Therapeutics. Dr Kelly is an Australian physician and serial biotechnology entrepreneur with over 30 years' experience in developing and commercialising biomedical innovations in the US, Europe, UK and Australia. While in the UK and US he led early-stage and mid-stage companies, public and private, with a record of achievement in transforming ideas, technologies and products into sustainable successful businesses and delivering strong returns for shareholders and investors as a founder and CEO.

Paul_Kelly_Garvan_Institute.png

Paul Kelly

Professor Benjamin Kile is the Executive Director of the Garvan Institute of Medical Research. He is an internationally recognised medical researcher who has made contributions to the understanding of cancer, stem cells and inflammatory disease. His work has shed light on the mechanisms of programmed cell death, informing the development of the BH3 mimetics, a new class of cancer drugs approved by the FDA in 2016. Professor Kile has a distinguished research leadership background, having occupied senior roles at the Walter and Eliza Hall Institute, Monash University, and the University of Adelaide. He made foundational contributions to the establishment of the National Drug Discovery Centre, the South Australian immunoGENomics Cancer Institute, and the Bragg Comprehensive Cancer Centre.

Benjamin_Kile_Garvan-Institute.png

Executive Director

Benjamin Kile

Dr Marshall is the Chief Strategy Officer at St Vincent’s Health Australia, responsible for strategy development and delivery across its portfolio of private hospitals, aged care services, research partnerships, and virtual and at-home care. Dr Marshall interrupted his medical training with the Royal Australasian College of Physicians to pursue a Master in Public Administration (Health Policy) at Columbia University, supported by a Fulbright Scholarship. From there, he joined Boston Consulting Group where he led strategy and transformation efforts for governments, hospital providers, private health insurers and other large public and private organisations in Australia and the UK. He has also worked on cost-effectiveness analyses as a Consultant to the World Health Organization and on health system reform as a Policy Advisor to the Department of Prime Minister and Cabinet.

Robert-Marshall_Garvan_Board

Robert Marshall

Ms McFadgen is the Chief Executive Officer, St Vincent’s Health Network Sydney. She joined St Vincent’s in 2018 and has held Executive roles in strategy, planning and business development across both St Vincent’s Public Hospital in Melbourne and more recently at St Vincent’s Health Network Sydney. Prior to joining St Vincent’s, Ms McFadgen held senior clinical operational roles at Austin Health in Victoria. She has over 20 years’ experience in the health sector in both strategy and clinical operations and is proud to lead the St Vincent’s Health Network Sydney Team in providing the best patient outcomes and experiences for our community.

Anna-M-Garvan-Board.jpg

Anna McFadgen

Nominated by the Federal Minister for Health

Reddel is a medical oncologist, molecular geneticist and an internationally renowned expert on cancer cell immortalisation. He is Executive Director of Children’s Medical Research Institute (CMRI), Westmead, the Sir Lorimer Dods Professor of the University of Sydney, and a Fellow of the Australian Academy of Science, the Australian Academy of Health and Medical Sciences, the Royal Society of NSW, and the Royal Australasian College of Physicians.

Roger_Reddel_Garvan_Institute.jpeg

Roger Reddel AO

Dr Scrimshaw is the Garvan Research Foundation Board Chairman and a Non-Executive Director of the Garvan Institute of Medical Research. He is currently Executive Chairman of Peak Rare Earths Ltd, Deputy Chairman of Ignition Wealth P/L, Non-Executive Chairman of ARI P/L and Scrimshaw Nominees P/L and also of Australian Philanthropic Fund, the Scrimshaw Foundation. Previously, he has held senior executive positions at Fortescue Metals Group Ltd (FMG), Commonwealth Bank, Optus and IBM. He was also Non-Executive Chairman at Sirius Minerals plc, and Executive Director at FMG, and Non-Executive Director of Commonwealth Properties Ltd, EDS Australia, Mobilesoft, Telecom New Zealand Australia P/L, and Athletics Australia.

Russell_Scrimshaw.JPG

Russell Scrimshaw AM

Professor Trent is Head of the Department of Medical Genomics at the Royal Prince Alfred Hospital and Director for the Institute of Precision Medicine & Bioinformatics at the Sydney Local Health District. He is the President of the School Council for the Sydney Boys High School, and past Secretary of the Sydney Girls High School Foundation. He is a fellow of the Royal Australasian College of Physicians, the Royal College of Pathologists of Australasia, and of the Australian Academy of Technology and Engineering.

_Ronald_Trent.png

Ronald Trent

Garvan Institute of Medical Research Act 1984

, Board Directors are nominated by Garvan's stakeholders and appointed by the Governor of New South Wales.

Garvan-Library-Overhead_Garvan-Institute.jpg

They are responsible for policy development and effective governance of the Institute's affairs.